<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39407643</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Effective Synthesis of mRNA during In Vitro Transcription with Fewer Impurities Produced.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4713</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules29194713</ELocationID><Abstract><AbstractText>The remarkable efficacy of COVID-19 vaccines has established mRNA as a highly promising biomedical technology. However, the adequate application of mRNA therapeutics necessitates additional measures to mitigate the inherent immunogenicity, which is predominantly caused by dsRNA. As a byproduct of the in vitro transcription of mRNA, dsRNA was reported to be originated through several distinct mechanisms, including the extension of 3' loop-back hairpins, the extension of hybridized abortive transcripts, and promoter-independent transcription. The intricate mechanisms involved pose a dilemma as the reduction in dsRNA results in a concomitant decrease in other critical quality attributes of mRNA. Here, we demonstrate that the promoter binding motifs of T7 RNA polymerase directly impact the production of promoter-independent transcription-based dsRNA. Specifically, the G753A mutation significantly reduces the formation of dsRNA byproducts, which can further combine with modified nucleotides to enhance the effectiveness of dsRNA mitigation and with previously reported high-integrity mutation K389A to minimize side effects. Accordingly, the present study reports a cost-effective approach to synthesize high-purity, less immunostimulatory mRNA by using an engineered T7 RNA polymerase mutant.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Forestry, Nanjing Forestry University, Nanjing 210037, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Guiying</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yucai</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7905-4217</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Changzhou University, Changzhou 213164, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Qiuheng</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-5869-0310</Identifier><AffiliationInfo><Affiliation>Vazyme Biotech Co., Ltd., Nanjing 210037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Jianren</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>College of Forestry, Nanjing Forestry University, Nanjing 210037, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C062210">bacteriophage T7 RNA polymerase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.6</RegistryNumber><NameOfSubstance UI="D012321">DNA-Directed RNA Polymerases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012330">RNA, Double-Stranded</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="Y">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012321" MajorTopicYN="Y">DNA-Directed RNA Polymerases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="Y">Transcription, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="Y">Viral Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="N">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012330" MajorTopicYN="N">RNA, Double-Stranded</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">dsRNA</Keyword><Keyword MajorTopicYN="N">impurities</Keyword><Keyword MajorTopicYN="N">in vitro transcription</Keyword><Keyword MajorTopicYN="N">mRNA</Keyword><Keyword MajorTopicYN="N">mRNA integrity</Keyword></KeywordList><CoiStatement>Wei He, Qi Geng, Guiying Ji, Ji Li, Dan Wang, and Qiuheng Jin are employed by Vazyme Biotech Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39407643</ArticleId><ArticleId IdType="pmc">PMC11477551</ArticleId><ArticleId IdType="doi">10.3390/molecules29194713</ArticleId><ArticleId IdType="pii">molecules29194713</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park J.W., Lagniton P.N.P., Liu Y., Xu R.H. mRNA vaccines for COVID-19: What, why and how. Int. J. Biol. Sci. 2021;17:1446–1460. doi: 10.7150/ijbs.59233.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.59233</ArticleId><ArticleId IdType="pmc">PMC8071766</ArticleId><ArticleId IdType="pubmed">33907508</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang E., Liu X., Li M., Zhang Z., Song L., Zhu B., Wu X., Liu J., Zhao D., Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 2022;7:94. doi: 10.1038/s41392-022-00950-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00950-y</ArticleId><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb Y.N. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81:495–501. doi: 10.1007/s40265-021-01480-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01480-7</ArticleId><ArticleId IdType="pmc">PMC7938284</ArticleId><ArticleId IdType="pubmed">33683637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary N., Weissman D., Whitehead K.A. mRNA vaccines for infectious diseases: Principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021;20:817–838. doi: 10.1038/s41573-021-00283-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00283-5</ArticleId><ArticleId IdType="pmc">PMC8386155</ArticleId><ArticleId IdType="pubmed">34433919</ArticleId></ArticleIdList></Reference><Reference><Citation>Gote V., Bolla P.K., Kommineni N., Butreddy A., Nukala P.K., Palakurthi S.S., Khan W. A Comprehensive Review of mRNA Vaccines. Int. J. Mol. Sci. 2023;24:2700. doi: 10.3390/ijms24032700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24032700</ArticleId><ArticleId IdType="pmc">PMC9917162</ArticleId><ArticleId IdType="pubmed">36769023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon S., Kwon M., Im S., Lee K., Lee H. mRNA vaccines: The most recent clinical applications of synthetic mRNA. Arch. Pharmacal Res. 2022;45:245–262. doi: 10.1007/s12272-022-01381-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-022-01381-7</ArticleId><ArticleId IdType="pmc">PMC9012156</ArticleId><ArticleId IdType="pubmed">35426547</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao L., Zhang Y., Huang L. mRNA vaccine for cancer immunotherapy. Mol. Cancer. 2021;20:41. doi: 10.1186/s12943-021-01335-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01335-5</ArticleId><ArticleId IdType="pmc">PMC7905014</ArticleId><ArticleId IdType="pubmed">33632261</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Z., Tian Y., Song J., An G., Yang P. mRNA Vaccines: The Dawn of a New Era of Cancer Immunotherapy. Front. Immunol. 2022;13:887125. doi: 10.3389/fimmu.2022.887125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.887125</ArticleId><ArticleId IdType="pmc">PMC9201022</ArticleId><ArticleId IdType="pubmed">35720301</ArticleId></ArticleIdList></Reference><Reference><Citation>Connolly C.D., Quinonez S.C., Ames E.G. Rare disease therapeutics: The future of medical genetics in a changing landscape. Genet. Med. 2023;25:100339. doi: 10.1016/j.gim.2022.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gim.2022.11.007</ArticleId><ArticleId IdType="pubmed">36476402</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkotoky S., Murali A. The highly efficient T7 RNA polymerase: A wonder macromolecule in biological realm. Int. J. Biol. Macromol. 2018;118:49–56. doi: 10.1016/j.ijbiomac.2018.05.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.05.198</ArticleId><ArticleId IdType="pubmed">29847782</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabó G.T., Mahiny A.J., Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol. Ther. 2022;30:1850–1868. doi: 10.1016/j.ymthe.2022.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2022.02.016</ArticleId><ArticleId IdType="pmc">PMC8856755</ArticleId><ArticleId IdType="pubmed">35189345</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa R., Chung Y.J., Rose J.P., Wang B.C. Crystal structure of bacteriophage T7 RNA polymerase at 3.3 Å resolution. Nature. 1993;364:593–599. doi: 10.1038/364593a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364593a0</ArticleId><ArticleId IdType="pubmed">7688864</ArticleId></ArticleIdList></Reference><Reference><Citation>Girbig M., Misiaszek A.D., Müller C.W. Structural insights into nuclear transcription by eukaryotic DNA-dependent RNA polymerases. Nat. Rev. Mol. Cell Biol. 2022;23:603–622. doi: 10.1038/s41580-022-00476-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-022-00476-9</ArticleId><ArticleId IdType="pubmed">35505252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra I. Bacterial RNA polymerase: A promising target for the discovery of new antimicrobial agents. Curr. Opin. Investig. Drugs. 2007;8:600–607.</Citation><ArticleIdList><ArticleId IdType="pubmed">17668362</ArticleId></ArticleIdList></Reference><Reference><Citation>Temiakov D., Tahirov T.H., Anikin M., McAllister W.T., Vassylyev D.G., Yokoyama S. Crystallization and preliminary crystallographic analysis of T7 RNA polymerase elongation complex. Acta Crystallogr. Sect. D Biol. Crystallogr. 2003;59:185–187. doi: 10.1107/S0907444902019777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1107/S0907444902019777</ArticleId><ArticleId IdType="pubmed">12499566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardner L.P., Mookhtiar K.A., Coleman J.E. Initiation, elongation, and processivity of carboxyl-terminal mutants of T7 RNA polymerase. Biochemistry. 1997;36:2908–2918. doi: 10.1021/bi962397i.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi962397i</ArticleId><ArticleId IdType="pubmed">9062120</ArticleId></ArticleIdList></Reference><Reference><Citation>Tunitskaya V.L., Kochetkov S.N. Structural-functional analysis of bacteriophage T7 RNA polymerase. Biochemistry. 2002;67:1124–1135. doi: 10.1023/a:1020911223250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1020911223250</ArticleId><ArticleId IdType="pubmed">12460110</ArticleId></ArticleIdList></Reference><Reference><Citation>Camperi J., Lippold S., Ayalew L., Roper B., Shao S., Freund E., Nissenbaum A., Galan C., Cao Q., Yang F., et al. Comprehensive Impurity Profiling of mRNA: Evaluating Current Technologies and Advanced Analytical Techniques. Anal. Chem. 2024;96:3886–3897. doi: 10.1021/acs.analchem.3c05539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.3c05539</ArticleId><ArticleId IdType="pmc">PMC10918618</ArticleId><ArticleId IdType="pubmed">38377434</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller M., Alvizo O., Baskerville S., Chintala A., Chng C., Dassie J., Dorigatti J., Huisman G., Jenne S., Kadam S., et al. An Engineered T7 RNA polymerase for Efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis. Faraday Discuss. 2024;252:431–449. doi: 10.1039/D4FD00023D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D4FD00023D</ArticleId><ArticleId IdType="pubmed">38832894</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu X., Hur S. Immunogenicity of In Vitro-Transcribed RNA. Acc. Chem. Res. 2021;54:4012–4023. doi: 10.1021/acs.accounts.1c00521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.accounts.1c00521</ArticleId><ArticleId IdType="pmc">PMC9127547</ArticleId><ArticleId IdType="pubmed">34677064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101–105. doi: 10.1038/nature04734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04734</ArticleId><ArticleId IdType="pubmed">16625202</ArticleId></ArticleIdList></Reference><Reference><Citation>Baiersdörfer M., Boros G., Muramatsu H., Mahiny A., Vlatkovic I., Sahin U., Karikó K. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids. 2019;15:26–35. doi: 10.1016/j.omtn.2019.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.02.018</ArticleId><ArticleId IdType="pmc">PMC6444222</ArticleId><ArticleId IdType="pubmed">30933724</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Muramatsu H., Ludwig J., Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39:e142. doi: 10.1093/nar/gkr695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkr695</ArticleId><ArticleId IdType="pmc">PMC3241667</ArticleId><ArticleId IdType="pubmed">21890902</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal A. From rejection to the Nobel Prize: Karikó and Weissman’s pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology. Front. Immunol. 2023;14:1306025. doi: 10.3389/fimmu.2023.1306025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1306025</ArticleId><ArticleId IdType="pmc">PMC10663363</ArticleId><ArticleId IdType="pubmed">38022662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav T., Kumar S., Mishra G., Saxena S.K. Tracking the COVID-19 vaccines: The global landscape. Hum. Vaccines Immunother. 2023;19:2191577. doi: 10.1080/21645515.2023.2191577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2191577</ArticleId><ArticleId IdType="pmc">PMC10101659</ArticleId><ArticleId IdType="pubmed">36995773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X. Detailed dissection and critical evaluation of the Pfizer/BioNTech and Moderna mRNA vaccines. Vaccines. 2021;9:734. doi: 10.3390/vaccines9070734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070734</ArticleId><ArticleId IdType="pmc">PMC8310186</ArticleId><ArticleId IdType="pubmed">34358150</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K.S., Flynn B., Foulds K.E., Francica J.R., Boyoglu-Barnum S., Werner A.P., Flach B., O’Connell S., Bock K.W., Minai M., et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N. Engl. J. Med. 2020;383:1544–1555. doi: 10.1056/NEJMoa2024671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2024671</ArticleId><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Karikó K., Muramatsu H., Welsh F.A., Ludwig J., Kato H., Akira S., Weissman D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008;16:1833–1840. doi: 10.1038/mt.2008.200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.200</ArticleId><ArticleId IdType="pmc">PMC2775451</ArticleId><ArticleId IdType="pubmed">18797453</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson B.R., Muramatsu H., Nallagatla S.R., Bevilacqua P.C., Sansing L.H., Weissman D., Karikó K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38:5884–5892. doi: 10.1093/nar/gkq347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkq347</ArticleId><ArticleId IdType="pmc">PMC2943593</ArticleId><ArticleId IdType="pubmed">20457754</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman D. mRNA transcript therapy. Expert Rev. Vaccines. 2015;14:265–281. doi: 10.1586/14760584.2015.973859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.973859</ArticleId><ArticleId IdType="pubmed">25359562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohner E., Yang R., Foo K.S., Goedel A., Chien K.R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 2022;40:1586–1600. doi: 10.1038/s41587-022-01491-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01491-z</ArticleId><ArticleId IdType="pubmed">36329321</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T., Klein L.J., Ha S., Rustandi R.R. High-Resolution capillary electrophoresis separation of large RNA under non-aqueous conditions. J. Chromatogr. A. 2020;1618:460875. doi: 10.1016/j.chroma.2020.460875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2020.460875</ArticleId><ArticleId IdType="pubmed">31982098</ArticleId></ArticleIdList></Reference><Reference><Citation>He W., Zhang X., Zou Y., Li J., Wang C., He Y., Jin Q., Ye J. Effective Synthesis of High-Integrity mRNA Using In Vitro Transcription. Molecules. 2024;29:2461. doi: 10.3390/molecules29112461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules29112461</ArticleId><ArticleId IdType="pmc">PMC11173937</ArticleId><ArticleId IdType="pubmed">38893337</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel S., Kis Z., Kontoravdi C., Shah N. Quality by Design for enabling RNA platform production processes. Trends Biotechnol. 2022;40:1213–1228. doi: 10.1016/j.tibtech.2022.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibtech.2022.03.012</ArticleId><ArticleId IdType="pubmed">35491266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kis Z. Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain. Pharmaceutics. 2022;14:430. doi: 10.3390/pharmaceutics14020430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14020430</ArticleId><ArticleId IdType="pmc">PMC8877932</ArticleId><ArticleId IdType="pubmed">35214162</ArticleId></ArticleIdList></Reference><Reference><Citation>Oivanen M., Kuusela S., Lönnberg H. Kinetics and Mechanisms for the Cleavage and Isomerization of the Phosphodiester Bonds of RNA by Brønsted Acids and Bases. Chem. Rev. 1998;98:961–990. doi: 10.1021/cr960425x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr960425x</ArticleId><ArticleId IdType="pubmed">11848921</ArticleId></ArticleIdList></Reference><Reference><Citation>Wayment-Steele H.K., Kim D.S., Choe C.A., Nicol J.J., Wellington-Oguri R., Watkins A.M., Parra Sperberg R.A., Huang P.S., Participants E., Das R. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 2021;49:10604–10617. doi: 10.1093/nar/gkab764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab764</ArticleId><ArticleId IdType="pmc">PMC8499941</ArticleId><ArticleId IdType="pubmed">34520542</ArticleId></ArticleIdList></Reference><Reference><Citation>Forconi M., Herschlag D. Metal Ion-Based RNA Cleavage as a Structural Probe. Methods Enzym. 2009;468:91–106. doi: 10.1016/s0076-6879(09)68005-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0076-6879(09)68005-8</ArticleId><ArticleId IdType="pubmed">20946766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu X., Greenwald E., Ahmad S., Hur S. An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res. 2018;46:5239–5249. doi: 10.1093/nar/gky177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky177</ArticleId><ArticleId IdType="pmc">PMC6007322</ArticleId><ArticleId IdType="pubmed">29534222</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B., Chen Y., Yan Y., Lu X., Zhu B. DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants. Nucleic Acids Res. 2024;52:8443–8453. doi: 10.1093/nar/gkae593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkae593</ArticleId><ArticleId IdType="pmc">PMC11317132</ArticleId><ArticleId IdType="pubmed">38979568</ArticleId></ArticleIdList></Reference><Reference><Citation>Durniak K.J., Bailey S., Steitz T.A. The structure of a transcribing T7 RNA polymerase in transition from initiation to elongation. Science. 2008;322:553–557. doi: 10.1126/science.1163433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1163433</ArticleId><ArticleId IdType="pmc">PMC2892258</ArticleId><ArticleId IdType="pubmed">18948533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sari Y., Sousa Rosa S., Jeffries J., Marques M.P.C. Comprehensive evaluation of T7 promoter for enhanced yield and quality in mRNA production. Sci. Rep. 2024;14:9655. doi: 10.1038/s41598-024-59978-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-59978-5</ArticleId><ArticleId IdType="pmc">PMC11053036</ArticleId><ArticleId IdType="pubmed">38671016</ArticleId></ArticleIdList></Reference><Reference><Citation>Temiakov D., Mentesana P.E., Ma K., Mustaev A., Borukhov S., McAllister W.T. The specificity loop of T7 RNA polymerase interacts first with the promoter and then with the elongating transcript, suggesting a mechanism for promoter clearance. Proc. Natl. Acad. Sci. USA. 2000;97:14109–14114. doi: 10.1073/pnas.250473197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.250473197</ArticleId><ArticleId IdType="pmc">PMC18879</ArticleId><ArticleId IdType="pubmed">11095736</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa R., Mukherjee S. T7 RNA polymerase. Prog. Nucleic Acid Res. Mol. Biol. . 2003;73:1–41. doi: 10.1016/s0079-6603(03)01001-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0079-6603(03)01001-8</ArticleId><ArticleId IdType="pubmed">12882513</ArticleId></ArticleIdList></Reference><Reference><Citation>McGraw N.J., Bailey J.N., Cleaves G.R., Dembinski D.R., Gocke C.R., Joliffe L.K., MacWright R.S., McAllister W.T. Sequence and analysis of the gene for bacteriophage T3 RNA polymerase. Nucleic Acids Res. 1985;13:6753–6766. doi: 10.1093/nar/13.18.6753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/13.18.6753</ArticleId><ArticleId IdType="pmc">PMC321991</ArticleId><ArticleId IdType="pubmed">3903658</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotani H., Ishizaki Y., Hiraoka N., Obayashi A. Nucleotide sequence and expression of the cloned gene of bacteriophage SP6 RNA polymerase. Nucleic Acids Res. 1987;15:2653–2664. doi: 10.1093/nar/15.6.2653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/15.6.2653</ArticleId><ArticleId IdType="pmc">PMC340675</ArticleId><ArticleId IdType="pubmed">3031606</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietz A., Weisser H.J., Kössel H., Hausmann R. The gene for Klebsiella bacteriophage K11 RNA polymerase: Sequence and comparison with the homologous genes of phages T7, T3, and SP6. Mol. Gen. Genet. MGG. 1990;221:283–286. doi: 10.1007/BF00261733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00261733</ArticleId><ArticleId IdType="pubmed">2370850</ArticleId></ArticleIdList></Reference><Reference><Citation>Li E., Wei X., Ma Y., Yin Z., Li H., Lin W., Wang X., Li C., Shen Z., Zhao R., et al. Isolation and characterization of a bacteriophage phiEap-2 infecting multidrug resistant Enterobacter aerogenes. Sci. Rep. 2016;6:28338. doi: 10.1038/srep28338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28338</ArticleId><ArticleId IdType="pmc">PMC4913238</ArticleId><ArticleId IdType="pubmed">27320081</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham G.M.T., Jeruzalmi D., Steitz T.A. Structural basis for initiation of transcription from an RNA polymerase-promoter complex. Nature. 1999;399:80–83. doi: 10.1038/19999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19999</ArticleId><ArticleId IdType="pubmed">10331394</ArticleId></ArticleIdList></Reference><Reference><Citation>Brieba L.G., Gopal V., Sousa R. Scanning mutagenesis reveals roles for helix n of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination. J. Biol. Chem. 2001;276:10306–10313. doi: 10.1074/jbc.M009866200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M009866200</ArticleId><ArticleId IdType="pubmed">11124963</ArticleId></ArticleIdList></Reference><Reference><Citation>Dousis A., Ravichandran K., Hobert E.M., Moore M.J., Rabideau A.E. An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory byproducts. Nat. Biotechnol. 2023;41:560–568. doi: 10.1038/s41587-022-01525-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-022-01525-6</ArticleId><ArticleId IdType="pmc">PMC10110463</ArticleId><ArticleId IdType="pubmed">36357718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain N., Blauch L.R., Szymanski M.R., Das R., Tang S.K.Y., Yin Y.W., Fire A.Z. Transcription polymerase-catalyzed emergence of novel RNA replicons. Science. 2020;368:eaay0688. doi: 10.1126/science.aay0688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay0688</ArticleId><ArticleId IdType="pmc">PMC7445081</ArticleId><ArticleId IdType="pubmed">32217750</ArticleId></ArticleIdList></Reference><Reference><Citation>Nance K.D., Meier J.L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. ACS Cent. Sci. 2021;7:748–756. doi: 10.1021/acscentsci.1c00197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00197</ArticleId><ArticleId IdType="pmc">PMC8043204</ArticleId><ArticleId IdType="pubmed">34075344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.Z., Asahara H., Tzertzinis G., Roy B. Synthesis of low immunogenicity RNA with high-temperature in vitro transcription. RNA. 2020;26:345–360. doi: 10.1261/rna.073858.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.073858.119</ArticleId><ArticleId IdType="pmc">PMC7025508</ArticleId><ArticleId IdType="pubmed">31900329</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao X., Yadav V., Wang E., Chang W., Tau L., Lindenmuth B.E., Wang S.X. Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA. Mol. Ther. Nucleic Acids. 2022;29:618–624. doi: 10.1016/j.omtn.2022.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.08.001</ArticleId><ArticleId IdType="pmc">PMC9421179</ArticleId><ArticleId IdType="pubmed">36090758</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.H., Potapov V., Dai N., Ong J.L., Roy B. N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs. Sci. Rep. 2022;12:13017. doi: 10.1038/s41598-022-17249-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17249-1</ArticleId><ArticleId IdType="pmc">PMC9335462</ArticleId><ArticleId IdType="pubmed">35906281</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>